From Groundbreaking Science to the Clinic From Groundbreaking Science to the Clinic From Groundbreaking Science to the Clinic

about receptos

Receptos is a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases. Our lead asset, RPC1063, is being developed as an oral therapy for relapsing multiple sclerosis (RMS) and inflammatory bowel disease (IBD). Receptos is currently enrolling a Phase 3 study in RMS called RADIANCE, and has completed enrollment in a Phase 2 study in ulcerative colitis (a form of IBD) called TOUCHSTONE. Receptos is conducting a Phase 2 trial for RPC4046, a monoclonal antibody directed against interleukin-13 (IL-13), in patients with eosinophilic esophagitis (EoE).

news

October 3, 2014
Receptos Announces First Patient Treated With Anti-Interleukin-13 Antibody in Phase 2 Trial for Eosinophilic Esophagitis… MORE »

September 10, 2014
Receptos Announces Oral Podium Presentation at MS Boston 2014… MORE »

August 12, 2014
Receptos Reports Second Quarter 2014 Financial Results… MORE »

August 8, 2014
Receptos to Present at Wedbush PacGrow Life Sciences Conference… MORE »